BioMarin Pharmaceutical Inc. (BMRN) Shares Sold by Virtus ETF Advisers LLC

Virtus ETF Advisers LLC decreased its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 25.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,453 shares of the biotechnology company’s stock after selling 2,247 shares during the period. Virtus ETF Advisers LLC’s holdings in BioMarin Pharmaceutical were worth $549,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of BMRN. Daiwa Securities Group Inc. increased its stake in shares of BioMarin Pharmaceutical by 136.6% in the fourth quarter. Daiwa Securities Group Inc. now owns 16,717 shares of the biotechnology company’s stock valued at $1,423,000 after purchasing an additional 9,650 shares during the period. Comerica Securities Inc. increased its stake in shares of BioMarin Pharmaceutical by 23.9% during the fourth quarter. Comerica Securities Inc. now owns 3,197 shares of the biotechnology company’s stock valued at $272,000 after acquiring an additional 617 shares during the period. Schmidt P J Investment Management Inc. increased its stake in shares of BioMarin Pharmaceutical by 8.2% during the fourth quarter. Schmidt P J Investment Management Inc. now owns 6,333 shares of the biotechnology company’s stock valued at $539,000 after acquiring an additional 480 shares during the period. Patriot Financial Group Insurance Agency LLC acquired a new position in shares of BioMarin Pharmaceutical during the fourth quarter valued at approximately $51,000. Finally, Financial Gravity Companies Inc. acquired a new position in shares of BioMarin Pharmaceutical during the fourth quarter valued at approximately $206,000.

In related news, Director V Bryan Lawlis sold 2,150 shares of the firm’s stock in a transaction that occurred on Thursday, December 27th. The shares were sold at an average price of $82.53, for a total value of $177,439.50. Following the completion of the transaction, the director now owns 21,310 shares of the company’s stock, valued at approximately $1,758,714.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jean Jacques Bienaime sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 12th. The stock was sold at an average price of $93.12, for a total transaction of $186,240.00. Following the completion of the transaction, the chief executive officer now directly owns 290,290 shares of the company’s stock, valued at approximately $27,031,804.80. The disclosure for this sale can be found here. Insiders have sold 33,150 shares of company stock valued at $2,969,730 over the last 90 days. 1.90% of the stock is currently owned by insiders.

NASDAQ:BMRN traded up $0.41 during trading hours on Wednesday, reaching $95.64. 6,590 shares of the company’s stock were exchanged, compared to its average volume of 890,569. The stock has a market capitalization of $17.13 billion, a price-to-earnings ratio of -143.26 and a beta of 1.63. BioMarin Pharmaceutical Inc. has a 12 month low of $75.81 and a 12 month high of $106.74. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.26 and a current ratio of 2.87.

BMRN has been the topic of a number of research analyst reports. Cantor Fitzgerald reiterated a “buy” rating and set a $126.00 price objective on shares of BioMarin Pharmaceutical in a research note on Sunday, November 4th. Wedbush set a $127.00 price objective on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research note on Monday, October 29th. Raymond James raised their price objective on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the company a “buy” rating in a research note on Friday, October 26th. Canaccord Genuity raised their price objective on shares of BioMarin Pharmaceutical from $113.00 to $116.00 and gave the company a “buy” rating in a research note on Tuesday, October 23rd. Finally, Jefferies Financial Group raised their price objective on shares of BioMarin Pharmaceutical to $125.00 and gave the company a “buy” rating in a research note on Tuesday, October 16th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have assigned a buy rating to the company. BioMarin Pharmaceutical has a consensus rating of “Buy” and a consensus price target of $113.34.

COPYRIGHT VIOLATION NOTICE: “BioMarin Pharmaceutical Inc. (BMRN) Shares Sold by Virtus ETF Advisers LLC” was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2019/02/13/biomarin-pharmaceutical-inc-bmrn-shares-sold-by-virtus-etf-advisers-llc.html.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.

See Also: Correction

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply